139 related articles for article (PubMed ID: 15718288)
1. Modulation of metoprolol pharmacokinetics and hemodynamics by diphenhydramine coadministration during exercise testing in healthy premenopausal women.
Sharma A; Pibarot P; Pilote S; Dumesnil JG; Arsenault M; Bélanger PM; Meibohm B; Hamelin BA
J Pharmacol Exp Ther; 2005 Jun; 313(3):1172-81. PubMed ID: 15718288
[TBL] [Abstract][Full Text] [Related]
2. Toward optimal treatment in women: the effect of sex on metoprolol-diphenhydramine interaction.
Sharma A; Pibarot P; Pilote S; Dumesnil JG; Arsenault M; Bélanger PM; Meibohm B; Hamelin BA
J Clin Pharmacol; 2010 Feb; 50(2):214-25. PubMed ID: 19948945
[TBL] [Abstract][Full Text] [Related]
3. Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity.
Hamelin BA; Bouayad A; Méthot J; Jobin J; Desgagnés P; Poirier P; Allaire J; Dumesnil J; Turgeon J
Clin Pharmacol Ther; 2000 May; 67(5):466-77. PubMed ID: 10824625
[TBL] [Abstract][Full Text] [Related]
4. Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics.
Kirchheiner J; Heesch C; Bauer S; Meisel C; Seringer A; Goldammer M; Tzvetkov M; Meineke I; Roots I; Brockmöller J
Clin Pharmacol Ther; 2004 Oct; 76(4):302-12. PubMed ID: 15470329
[TBL] [Abstract][Full Text] [Related]
5. Gender-related effects on metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers.
Luzier AB; Killian A; Wilton JH; Wilson MF; Forrest A; Kazierad DJ
Clin Pharmacol Ther; 1999 Dec; 66(6):594-601. PubMed ID: 10613615
[TBL] [Abstract][Full Text] [Related]
6. Debrisoquine phenotype and the pharmacokinetics and beta-2 receptor pharmacodynamics of metoprolol and its enantiomers.
Jonkers RE; Koopmans RP; Portier EJ; van Boxtel CJ
J Pharmacol Exp Ther; 1991 Mar; 256(3):959-66. PubMed ID: 1848636
[TBL] [Abstract][Full Text] [Related]
7. Impact of the CYP2D6 genotype on the clinical effects of metoprolol: a prospective longitudinal study.
Rau T; Wuttke H; Michels LM; Werner U; Bergmann K; Kreft M; Fromm MF; Eschenhagen T
Clin Pharmacol Ther; 2009 Mar; 85(3):269-72. PubMed ID: 19037197
[TBL] [Abstract][Full Text] [Related]
8. Pantoprazole has no influence on steady state pharmacokinetics and pharmacodynamics of metoprolol in healthy volunteers.
Koch HJ; Hartmann M; Bliesath H; Huber R; Steinijans VW; Mascher H; Wurst W
Int J Clin Pharmacol Ther; 1996 Oct; 34(10):420-3. PubMed ID: 8897078
[TBL] [Abstract][Full Text] [Related]
9. An investigation of CYP2D6 genotype and response to metoprolol CR/XL during dose titration in patients with heart failure: a MERIT-HF substudy.
Batty JA; Hall AS; White HL; Wikstrand J; de Boer RA; van Veldhuisen DJ; van der Harst P; Waagstein F; Hjalmarson Å; Kjekshus J; Balmforth AJ;
Clin Pharmacol Ther; 2014 Mar; 95(3):321-30. PubMed ID: 24193112
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers.
Preskorn S; Patroneva A; Silman H; Jiang Q; Isler JA; Burczynski ME; Ahmed S; Paul J; Nichols AI
J Clin Psychopharmacol; 2009 Feb; 29(1):39-43. PubMed ID: 19142106
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic and pharmacodynamic interactions between metoprolol and dronedarone in extensive and poor CYP2D6 metabolizers healthy subjects.
Damy T; Pousset F; Caplain H; Hulot JS; Lechat P
Fundam Clin Pharmacol; 2004 Feb; 18(1):113-23. PubMed ID: 14748763
[TBL] [Abstract][Full Text] [Related]
12. Enantiospecific pharmacokinetics of metoprolol in CYP2D6 ultra-rapid metabolizers and correlation with exercise-induced heart rate.
Seeringer A; Brockmöller J; Bauer S; Kirchheiner J
Eur J Clin Pharmacol; 2008 Sep; 64(9):883-8. PubMed ID: 18545991
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and QT interval pharmacodynamics of oral haloperidol in poor and extensive metabolizers of CYP2D6.
Desai M; Tanus-Santos JE; Li L; Gorski JC; Arefayene M; Liu Y; Desta Z; Flockhart DA
Pharmacogenomics J; 2003; 3(2):105-13. PubMed ID: 12746736
[TBL] [Abstract][Full Text] [Related]
14. Impact of CYP2D6 poor metabolizer phenotype on propranolol pharmacokinetics and response.
Sowinski KM; Burlew BS
Pharmacotherapy; 1997; 17(6):1305-10. PubMed ID: 9399616
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetic determination of the effects of codeine and prediction of drug interactions.
Caraco Y; Sheller J; Wood AJ
J Pharmacol Exp Ther; 1996 Sep; 278(3):1165-74. PubMed ID: 8819499
[TBL] [Abstract][Full Text] [Related]
16. Influence of CYP2D6-dependent metabolism on the steady-state pharmacokinetics and pharmacodynamics of metoprolol and nicardipine, alone and in combination.
Laurent-Kenesi MA; Funck-Brentano C; Poirier JM; Decolin D; Jaillon P
Br J Clin Pharmacol; 1993 Dec; 36(6):531-8. PubMed ID: 12959269
[TBL] [Abstract][Full Text] [Related]
17. Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study.
Fux R; Mörike K; Pröhmer AM; Delabar U; Schwab M; Schaeffeler E; Lorenz G; Gleiter CH; Eichelbaum M; Kivistö KT
Clin Pharmacol Ther; 2005 Oct; 78(4):378-87. PubMed ID: 16198657
[TBL] [Abstract][Full Text] [Related]
18. Human pharmacology of the methamphetamine stereoisomers.
Mendelson J; Uemura N; Harris D; Nath RP; Fernandez E; Jacob P; Everhart ET; Jones RT
Clin Pharmacol Ther; 2006 Oct; 80(4):403-20. PubMed ID: 17015058
[TBL] [Abstract][Full Text] [Related]
19. Effect of metoprolol and verapamil administered separately and concurrently after single doses on liver blood flow and drug disposition.
Bauer LA; Horn JR; Maxon MS; Easterling TR; Shen DD; Strandness DE
J Clin Pharmacol; 2000 May; 40(5):533-43. PubMed ID: 10806607
[TBL] [Abstract][Full Text] [Related]
20. Effects of paroxetine on the pharmacokinetics and pharmacodynamics of immediate-release and extended-release metoprolol.
Parker RB; Soberman JE
Pharmacotherapy; 2011 Jul; 31(7):630-41. PubMed ID: 21923449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
